IGC Pharma, Inc.
IGC · AMEX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,271 | $1,345 | $911 | $397 |
| % Growth | -5.5% | 47.6% | 129.5% | – |
| Cost of Goods Sold | $652 | $612 | $1,069 | $203 |
| Gross Profit | $619 | $733 | -$158 | $194 |
| % Margin | 48.7% | 54.5% | -17.3% | 48.9% |
| R&D Expenses | $3,655 | $3,773 | $3,461 | $2,330 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4,410 | $6,758 | $7,952 | $13,292 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,065 | $10,531 | $11,413 | $15,622 |
| Operating Income | -$7,446 | -$9,798 | -$11,571 | -$15,428 |
| % Margin | -585.8% | -728.5% | -1,270.1% | -3,886.1% |
| Other Income/Exp. Net | $325 | -$3,202 | $65 | $412 |
| Pre-Tax Income | -$7,121 | -$13,000 | -$11,506 | -$15,016 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,121 | -$13,000 | -$11,506 | -$15,016 |
| % Margin | -560.3% | -966.5% | -1,263% | -3,782.4% |
| EPS | -0.093 | -0.22 | -0.22 | -0.3 |
| % Growth | 57.7% | 0% | 26.7% | – |
| EPS Diluted | -0.093 | -0.22 | -0.22 | -0.3 |
| Weighted Avg Shares Out | 76,517 | 58,840 | 52,576 | 49,992 |
| Weighted Avg Shares Out Dil | 76,517 | 58,840 | 52,576 | 49,992 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $618 | $637 | $657 | $651 |
| EBITDA | -$6,828 | -$9,161 | -$10,849 | -$14,365 |
| % Margin | -537.2% | -681.1% | -1,190.9% | -3,618.4% |